{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0"}]}],"title":"The Cumulative Incidence of Relapse at five year p"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6"}]}],"title":"Estimate±SE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The Cumulative Incidence of Relapse will be reported as the proportion of number of relapses since transplant to the total number of patients at risk at five years post-transplant.","groups":[{"description":"Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.","id":"OG000","title":"High-Risk Hematologic Malignancies"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"five years post-transplant","title":"To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}